SCD1 inhibitor-1 is primarily utilized in research and development focused on metabolic disorders and cancer. It targets the enzyme stearoyl-CoA desaturase-1 (SCD1), which plays a critical role in lipid metabolism. By inhibiting SCD1, it helps regulate fatty acid composition, making it a potential therapeutic candidate for conditions like obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD). Additionally, its role in modulating lipid biosynthesis has drawn interest in oncology, as SCD1 inhibition can disrupt cancer cell proliferation and survival. Researchers also explore its potential in improving insulin sensitivity and reducing inflammation in metabolic syndrome. Its applications are largely experimental, with ongoing studies to validate its efficacy and safety in clinical settings.